Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis

Environmental and Molecular Mutagenesis

Volumn 49, Issue 3, 2008, Pages 226-231

  Kang, Shan ^a   Zhao, Xiwa ^a   Xing, Huimin ^a   Wang, Na ^b   Zhou, Rongmiao ^b   Chen, Shucheng ^a   Li, Wansheng ^a   Zhao, Jian ^a   Duan, Yanan ^b   Sun, Donglan ^b   Li, Yan ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Cancer Institute   (China)

Author keywords

Adenomyosis; MMP 2; Risk; SNP; TIMP 2

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADENOMYOSIS; ADULT; ALLELE; ARTICLE; CHINESE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; ENDOMETRIOSIS; FEMALE; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UTERINE DISEASES;

EID: 41849100005     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20375     Document Type: Article

References (34)

1. Aimes RT, Quigley JP. 1995. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270:5872-5876.
2. Bergholt T, Eriksen L, Berendt N, Jacobsen M, Hertz JB. 2001. Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod 16:2418-2421.
3. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. 1993. Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4:197-250.
4. Chambers AF, Matrissian LM. 1997. Changing views of the role of matrix metalloproteinase in metastasis. J Natl Cancer Inst (Bethesda) 89:1260-1270.
5. DeClerck YA, Darville MI, Eeckhout Y, Rousseau GG. 1994. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 139:185-191.
6. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
7. Faisst S, Meyer S. 1992. Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res 20:3-26.
8. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. 1997. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74:111-122.
9. Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, Mochizuki M, Kimura T, Saitoh W, Kiwamoto T, Iizuka T, Massoud HH, Massoud HM, Hassanein KM, Sekizawa K. 2005. Association analysis of tissue inhibitor of metalloproteinase 2 genepolymorphisms with COPD in Egyptians. Respir Med 99: 107-110.
10. Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, Nomura A, Ohtsuka M, Sekizawa K. 2001. Tissue inhibitorof metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 18:748-752.
11. Holla LI, Fassmann A, Vasku A, Goldbergova M, Beranek M, Znojil V, Vanek J, Vacha J. 2005. Genetic variations in the human gelatinase A (matrix metalloproteinase-2) promoter are not associated with susceptibility to, and severity of, chronic periodontitis. J Periodontol 76:1056-1060.
12. Kang S, Zhuo LF, Du H, Guo W, Wang N, Jin X, Li Y. 2006. Polymorphisms in the promoter regions of the matrix metalloproteinase -7, -9 and the risk of endometriosis and adenomyosis in China. Mol Hum Reprod 12:35-39.
13. Levi E, Fridman R, Miao HQ, Ma YC, Yayon A, Voldavsky I. 1996. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 93:7069-7074.
14. Li T, Li YG, Pu DM. 2006. Matrix Metalloproteinase-2 and -9 expression correlated with angiogenesis in human adenomyosis. Gynecol Obstet Invest 62:229-235.
15. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW. 2004. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 33:405-409.
16. Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D. 2003. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63:3987-3990.
17. Miller SA, Dybes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215
18. Nemec P, Goldbergova M, Swobodnik T, Polaskova D, Soucek M, Vasku A. 2006. Polymorphism of gene promotor region for MMP-2 in rheumatoid arthritis. Vnitr Lek 52:348-354.
19. O-Charoenrat P, Khantapura P. 2006. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42:257-267.
20. Parazzini F, Vercellini P, Panazza S, Chatenoud L, Oldani S, Crosignani PG. 1997. Risk factors for adenomyosis. Hum Reprod 12:1275-1279.
21. Price SJ, Greaves DR, Watkins H. 2000. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: Role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276:7549-7558.
22. Qin H, Sun Y, Benveniste EN. 1999. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells J Biol Chem 274:29130-29137.
23. Qiu F, Gao XM, Luo GL, Yang KX, Wang H, Liu H, Wen Y. 2006. Expression of matrix metalloproteinase and tissue inhibitor of metalloproteinase in adenomyosis. Sichuan Da Xue Xue Bao Yi Xue Ban 37:118-122.
24. Rollin J, Regina S, Vourc'h P, Iochmann S, Blechet C, Reverdiau P, Gruel Y. 2007. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 56:273-280.
25. Seidman JD, Kjerulff KH. 1996. Pathologic findings from the Maryland Women's Health Study: Practice patterns in the diagnosis of adenomyosis. Int J Gynecol Pathol 15:217-221.
26. Shaikh H, Khan KS. 1990. Adenomyosis in pakistani women: Four year experience at the Aga Khan University Medical Centre, Karachi. J Clin Pathol 43:817-819.
27. Stamenkovic I. 2000. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415-433.
28. Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW, Patsouris E. 2007. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17:963-968.
29. Wu CY, Wu MS, Chen YJ, Chen CJ, Chen HP, Shun CT, Chen GH, Huang SP, Lin JT. 2007. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 43:799-808.
30. Xu E, Lai M, Lv B, Xing X, Huang Q, Xia X. 2004. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 324:999-1003.
31. Ye S. 2000. Polymorphism in matrix metalloproteinase gene promoters: Implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19:623-629.
32. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. 2004. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622-7628.
33. Zhou Y, Yu C, Miao X, Tan W, Liang G, Xiong P, Sun T, Lin D. 2004. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25:399-404.
34. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. 2005. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 26:117-1121.